AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients

RecruitingPhase 2, Phase 3Ages 18 Years - anyAllJikei University School of Medicine
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This clinical trial aims to investigate whether the low treatment intensity (12 mL/kg/hr, low-dose hemodialysis/filtration) or the medium treatment intensity (25 mL/kg/hr, standard-dose hemodialysis/filtration) is more effective and safer for continuous renal replacement therapy in critically ill patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Patient who meets all of the following criteria and who has given informed consent. 1. Adults (18 years of age or older, regardless of the time since ICU admission) currently admitted to an intensive care unit\*. \*Includes high care units, where continuous monitoring is conducted and intensive care physicians are in charge of medical care. 2. A diagnosis of acute kidney injury is made according to the Kidney Disease: Improving Global Outcomes (KDIGO) international diagnostic criteria (one of the following is met) * Serum creatinine increased by more than 0.3 mg/dL within 48 hours * Serum creatinine increased more than 1.5-fold from baseline and the increase is considered to have occurred within 7 days * Oliguria (\< 0.5 mL/kg/hr) lasting more than 6 hours 3. The treating intensivist believes that continuous kidney replacement therapy is necessary Exclusion Criteria: Patient who meets any of the following exclusion criteria will be excluded. 1. Receiving chronic dialysis or scheduled for initiation of chronic dialysis 2. Undergoing any kidney replacement therapy or blood purification therapy within 48 hours 3. When kidney replacement therapy using other dialysate or replacement fluids, such as citrate dialysis, is preferred due to coexisting bleeding disorders or allergy to acetate 4. Concomitant blood purification therapy other than hemofiltration/dialysis, such as plasma exchange 5. The patient is in a very critical condition and the treating physician believes that survival for more than 24 hours is unlikely 6. Previous participation in the study 7. After receiving a full explanation of the study and with full understanding, a patient do not consent to participate in the study of their own (or their substitute decision maker's) will. 8. The principal investigator (or an investigator) thinks it to be inappropriate to participate in this study.
๐Ÿ’Š

What it tests

  • Dialysate fluid, Filtration replacement fluid
๐Ÿ“

Where

9 sites
Sendai Medical Center
Sendai, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Japan
University of Fukui Hospital
Fukui, Japan
Tsuchiura Kyodo General Hospital
Ibaraki, Japan
Osaka University Hospital
Osaka, Japan
Jichi Medical University Hospital
Tochigi, Japan
Jikei University Hospital
Tokyo, Japan
Keio University Hospital
Tokyo, Japan

โ€ฆand 1 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy